Clinical Trial Update: Candonilimab in Combination With LM-302 for Claudin 18.2 Positive-advanced Biliary Tract Cancer After Failure of Standard of Chemotherapy and PD1/PD-L1 Antibody [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for a phase 1/2 study of Candonilimab in combination with LM-302 for Claudin 18.2 positive advanced biliary tract cancer after failure of …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer

Drugs mentioned

• Candonilimab
• LM-302

Snippet

Sponsor: Shanghai Zhongshan Hospital | Conditions: Biliary Tract Cancer, Candonilimab | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING